MedTrace Logo

Assessment and Prevention of Pain During Ovarian Stimulation in Patients With Endometriosis

NCT04002141 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-01-28

Study results available
· View outcomes & findings →

Summary

Randomized double blinded placebo-controlled trial to evaluate the impact of ovarian hyperstimulation on endometriosis-related symptoms and to evaluate the impact of letrozole use during ovarian hyperstimulation with respect to endometriosis-related symptoms, embryo/egg quality and quantity, and pregnancy rates.

Conditions

  • Endometriosis
  • Ovarian Hyperstimulation

Interventions

DRUG

Placebo oral tablet

1 tablet oral daily

DRUG

Letrozole

5mg oral daily

Sponsors & Collaborators

Principal Investigators

  • Marcelle I Cedars · University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
42 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-09-17
Primary Completion
2023-10-01
Completion
2025-01-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04002141 on ClinicalTrials.gov